FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation

Phase 2 Completed 118 enrolled Federation Francophone de Cancerologie Digestive Amgen · collab

NaSingle-groupOpen-labelTreatment

Single-arm, multi-centre phase II study The primary objective is to evaluate the time to failure of the strategy.

Evaluation	Drug	Modality	Dose	Route
Subject	Oxaliplatin	Small molecule	85 mg/m2	Intravenous
Subject	Panitumumab	Monoclonal antibody	6 mg/kg	Intravenous
Background	Acide folinique	Unknown	200 mg/m2	Intravenous
Background	Acide folinique	Unknown	400 mg/m2	Intravenous
Background	fluorouracil	Small molecule	400 mg/m2	Intravenous
Background	fluorouracil	Small molecule	2400 mg/m2	Intravenous